Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: Follow-up data from the ALERT study

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2571-2575

  Svensson, My ^a   Dahle, Dag Olav ^b   Mjøen, Geir ^b   Weihrauch, Gisela ^c   Scharnagl, Hubert ^c   Dobnig, Harald ^c   März, Winfried ^c,d,e   Jardine, Alan ^f   Fellström, Bengt ^g   Holdaas, Hallvard ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Mortality; Osteoprotegerin; Renal transplantation vascular calcification

Indexed keywords

CREATININE; FLUINDOSTATIN; OSTEOPROTEGERIN; PLACEBO;

ADULT; ALL CAUSE MORTALITY; ARTICLE; CARDIAC MORTALITY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HAZARD RATIO; HUMAN; INTERVENTION STUDY; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INDOLES; INTERVENTION STUDIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; VASCULAR CALCIFICATION;

EID: 84861866232     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr694     Document Type: Article

References (33)

1. Hruska KA, Choi ET, Memon I et al. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 2010; 25: 769-778
2. Demer L, Tintut Y. The bone-vascular axis in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 349-353
3. Covic A, Kanbay M, Voroneanu L et al. Vascular calcification in chronic kidney disease. Clin Sci (Lond) 2010; 119: 111-121
4. Pilmore H, Dent H, Chang S et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89: 851-857
5. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319
6. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
7. Venuraju SM, Yerramasu A, Corder R et al. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55: 2049-2061
8. Golledge J, McCann M, Mangan S et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35: 1636-1641
9. Sandberg WJ, Yndestad A, Oie E et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-863
10. Jorsal A, Tarnow L, Flyvbjerg A et al. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100-2107
11. Ueland T, Jemtland R, Godang K et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1970-1976
12. Omland T, Ueland T, Jansson AM et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633
13. Anand DV, Lahiri A, Lim E et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857
14. Van CA, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-329
15. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525-532
16. Morena M, Dupuy AM, Jaussent I et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009; 24: 3389-3397
17. Bargnoux AS, Dupuy AM, Garrigue V et al. Renal transplantation decreases osteoprotegerin levels. Transplant Proc 2006; 38: 2317-2318
18. Hjelmesaeth J, Ueland T, Flyvbjerg A et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006; 17: 1746-1754
19. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031
20. Holdaas H, Fellstrom B, Holme I et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001; 8: 63-71
21. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008; 159: 603-608
22. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
23. BrownerWS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637
24. Sigrist MK, Levin A, Er L et al. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009; 24: 3157-3162
25. Nishiura R, Fujimoto S, Sato Y et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 2009; 29: 257-263
26. Cianciolo G, La Manna G, Donati G et al. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Blood Purif 2010; 29: 13-22
27. Bargnoux AS, Dupuy AM, Garrigue V et al. Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. Am J Transplant 2009; 9: 2571-2579
28. DeLoach SS, Joffe MM, Mai X et al. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 2009; 24: 1314-1319
29. Morony S, Tintut Y, Zhang Z et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117: 411-420
30. Upadhyay A, Larson MG, Guo CY et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011; 26: 920-926
31. Sato T, Tominaga Y, Iwasaki Y et al. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 2001; 38: S175-S177
32. Nellemann B, Gormsen LC, Dollerup J et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 2007; 30: 3122-3124
33. Dimitrow PP, Jawien M, Gackowski A. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J Heart Valve Dis 2011; 20: 18-22